Capability
Small Molecule Drug Product CDMOs
Compare CDMOs specializing in small molecule drug product formulation, tableting, encapsulation, and coating. Filter by dosage form, batch size, and regulatory approvals.
407 companies listed
Small molecule drug product manufacturing turns your API into the tablet, capsule, or injectable a patient actually takes. The hard part isn't making one clinical batch. It's finding a partner who can carry the process from a 20,000-unit Phase I lot to a validated commercial line without a mid-program tech transfer that resets your timeline. Ask three things before you shortlist. Does the CDMO run your dosage form at both clinical and commercial scale under one roof? If your molecule is BCS Class II or IV, do they have real bioavailability-enhancement experience (spray drying, hot melt extrusion, amorphous solid dispersions), or just a brochure? And can they show a batch record and stability package that held up under an FDA pre-approval inspection? The CDMOs below list small molecule drug product as a core capability.
About Small Molecule Drug Product Manufacturing
Small molecule drug product manufacturing transforms the API into the final dosage form patients receive. This includes granulation, blending, compression (tablets), encapsulation, film coating, and packaging. Each step requires precise process control to ensure dose uniformity, dissolution performance, and stability.
Bioavailability enhancement is a growing need. Many new chemical entities have poor aqueous solubility (BCS Class II/IV), requiring advanced formulation technologies: spray drying, hot melt extrusion, nanoparticle milling, amorphous solid dispersions, and lipid-based drug delivery systems. CDMOs with these capabilities command premium positioning.
Companies (407)
Catalent Pharma Solution
Argentina
Catalent is a leading global CDMO trusted by pharma, biotech, and self-care companies to accelerate the development, manufacturing, and delivery of products that improve lives. With a worldwide network of facilities, advanced technologies, and deep expertise, Catalent provides integrated end-to-end solutions spanning oral dose, biologics, specialty therapies, cell and gene therapy, and clinical supply. The company partners with innovators from early-stage design through commercial manufacturing.
Small Molecule Drug ProductOral Solid DoseFormulation Development
Celltrion
South Korea
Celltrion is a major South Korean biopharmaceutical company offering CDMO services for biologics, biosimilars, and small molecules. The company operates production capacities from 1,000L to 15,000L with a 98.5% batch success rate across 2,100+ cGMP drug substance batches, holding 400+ regulatory approvals in 90+ countries. Celltrion recently acquired Eli Lilly's Branchburg, New Jersey facility and launched Celltrion BioSolutions as a dedicated CDMO subsidiary, with plans to expand DS capacity to 132,000L by 2030.
Frequently Asked Questions
What equipment is needed for oral solid dose manufacturing?+
Core equipment includes: high-shear granulators, fluid bed processors, roller compactors (for dry granulation), tablet presses (rotary for high-volume, single-station for development), capsule fillers, film coating systems (pan coaters), blenders, and packaging lines. For modified-release products, add multiparticulate processing equipment (pelletizers, coating systems for beads/pellets).
How do you select a drug product CDMO for clinical vs commercial?+
Clinical-stage needs: flexibility, small batch capability (5,000-50,000 units), fast turnaround, and regulatory filing support. Commercial-stage needs: high-throughput equipment, validated processes, supply chain reliability, and cost efficiency at scale. Some CDMOs cover both stages; others specialize. Plan your CDMO strategy to minimize tech transfers between clinical and commercial.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
